Form 4: ATYR Pharma Director Acquires Stock Options

ATYR Pharma director Sara Zaknoen acquired 50,000 stock options with an exercise price of $0.95, vesting in full on May 11, 2027, or the 2027 Annual Meeting.

Summary

• Sara Zaknoen, a Director at ATYR Pharma Inc., acquired 50,000 stock options on May 11, 2026.
• The stock options have an exercise price of $0.95 per share.
• These options are part of the Issuer's non-employee director compensation policy.
• The options will vest in full on the earlier of May 11, 2027, or the company's 2027 Annual Meeting of Stockholders, contingent upon continued service on the Board of Directors.
• The underlying securities are 50,000 shares of Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it pertains to standard director compensation and does not provide new financial or strategic information about the company's performance.

Positives

• Director compensation aligns with long-term commitment through stock options.
• The acquisition of options by a director can signal confidence in the company's future prospects.

Negatives

• The filing only details the acquisition of options, not the company's financial performance or operational updates.

Risks

• The vesting of options is contingent on continued service, meaning a director's departure before the vesting date would result in forfeiture.
• The value of the options is subject to the future stock price performance of ATYR Pharma.

Future Outlook

The future outlook is tied to the vesting of the stock options, which depends on the reporting person's continued service and the company's performance leading up to May 11, 2027, or the 2027 Annual Meeting.

Industry Context

StockSavvy.ai notes that the issuance of stock options to non-employee directors is a common practice in the biotechnology and pharmaceutical sectors to incentivize long-term alignment with shareholder interests and retain key leadership.

Corporate Governance

Related Party Transactions

• The acquisition of stock options by Director Sara Zaknoen is a related party transaction, governed by the company's non-employee director compensation policy.

Stakeholder Impact

• Shareholders: The grant of options does not immediately dilute share count but represents potential future dilution if exercised. It aligns director incentives with stock performance.
• Employees: No direct impact mentioned.
• Management: Reinforces standard compensation practices for directors.

Next Steps

• Continued service by Sara Zaknoen on the ATYR Pharma Board of Directors until at least May 11, 2027, or the 2027 Annual Meeting for options to vest.
• Potential exercise of stock options by Sara Zaknoen if the stock price exceeds the $0.95 exercise price after vesting.

Key Dates

Keywords

ATYR Pharma, Form 4, Stock Options, Director Compensation, Beneficial Ownership, SEC Filing, Insider Trading